Evaluation of the discriminative stimulus effects of the low-affinity N-methyl-D-aspartate channel blockers AR-R 13950AA and AR-R 16283AA in rats and rhesus monkeys

Behavioural Pharmacology

Volumn 13, Issue 7, 2002, Pages 571-581

  Nicholson, Katherine L ^a   Balster, R L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AR R 13950AA; AR R 16283AA; Drug discrimination; NMDA antagonists; NPC 17742; Phencyclidine; Rat; Rhesus monkey

Indexed keywords

2 AMINO 4,5 (1,2 CYCLOHEXYL) 7 PHOSPHONOHEPTANOIC ACID; ARR 13950AA; ARR 16283AA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMPETITION; DRUG DISCRIMINATION; DRUG EFFECT; DRUG INTOXICATION; DRUG SCREENING; FOOD; HUMAN; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY; REINFORCEMENT; RHESUS MONKEY; STIMULUS; TRAINING; TREATMENT OUTCOME;

EID: 0036855719     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200211000-00006     Document Type: Article

References (37)

1. Balster RL (1991). Discriminative stimulus properties of phencyclidine and other NMDA antagonists. In: Drug Discrimination: Applications to Drug Abuse Research. Glennon RA, Järbe TUC, Frankenheim J (editors), National Institute on Drug Abuse Research Monograph Series 116, DHHS Publication No. (ADM) 92-1878. Washington DC, US Government Printing Office, pp. 163-180.
2. Balster RL, Willetts J (1996). Phencyclidine: A drug of abuse and a tool for neuroscience research. In: Pharmacological Aspects of Drug Dependence: Towards an Integrated Neurobehavioral Approach. Schuster CR, Kuhar MJ (editors), Handbook of Experimental Pharmacology, Vol. 118. Berlin, Springer-Verlag, pp. 233-262.
3. Balster RL, Mansbach RS, Shelton KL, Nicholson KL, Grech DM, Wiley JL et al. (1995). Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav Pharmacol 6:577-589.
4. Beardsley PM, Balster RL, Salay JM (1987). Separation of the response rate and discriminative stimulus effects of phencyclidine: Training dose as a factor in phencyclidine-saline discrimination. J Pharmacol Exp Ther 241:159-165.
5. Beardsley PM, Hayes BA, Balster RL (1990). The self-administration of MK-801 can depend upon drug-reinforcement history and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. J Pharmacol Exp Ther 252:953-959.
6. Bespalov AY, Beardsley PM, Balster RL (1998). Interactions between N-methyl-D-aspartate receptor antagonists and the discriminative stimulus effects of morphine in rats. Pharmacol Biochem Behav 60:507-517.
7. Bobelis DJ, Balster RL (1993). Pharmacological specificity of the discriminative stimulus properties of 2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid (NPC 12626), a competitive N-methyl-D-aspartate receptor antagonist. J Pharmacol Exp Ther 264:845-853.
8. Brady KT, Balster RL, May EL (1982). Stereoisomers of N-allylnormetazocine: Phencyclidine-like behavioral effects in squirrel monkeys and rats. Science 212:178-180.
9. Chen H-SV, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992). Open-channel block of the N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA-receptor mediated neurotoxicity. J Neurosci 12:4427-4436.
10. Ferkany JW, Kyle DJ, Willetts J, Rzeszotarski WJ, Guzewska ME, Ellenberger SR et al. (1989). Pharmacological profile of NPC 12626, a novel, competitive N-methyl-D-aspartate receptor antagonist. J Pharmacol Exp Ther 250:100-109.
11. Garske GE, Palmer GC, Napier J, Griffith RC, Freedman LR, Harris EW et al. (1991). Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat. Epilepsy Res 9:161-174.
12. Grant KA, Colombo G, Grant J, Rogawski MA (1996). Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology 35:1709-1719.
13. Greene JG, Porter RHP, Greenamyre JT (1996). ARL-15896, a novel N-methyl-D-aspartate receptor ion channel antagonist, neuroprotection against mitochondrial metabolic toxicity and regional pharmacology. Exp Neurol 137:66-72.
14. Holtzman SG (1990). Discriminative stimulus effects of drugs: Relationship to potential for abuse. In: Testing and Evaluation of Drugs of Abuse. Adler MA, Cowan A (editors). New York: Wiley-Liss. pp. 193-210.
15. Hudzik TJ, Freedman L, Palmer GC (1996). Remacemide hydrochloride and ARL 15896AR lack abuse potential: Additional differences from other uncompetitive NMDA antagonists. Epilepsia 37:544-550.
16. Jones HE, Li H, Balster RL (1998). Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys. Pharmacol Biochem Behav 59:413-418.
17. Koek W, Colpaert FC, Vignon J (1993). Effects of phencyclidine-type drugs in rats discriminating fentanyl from saline: Pharmacological and behavioral characterization of intermediate levels of drug lever selection. J Pharmacol Exp Therap 264:746-756.
18. Le DA, Lipton SA (2001). Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging 18:717-724.
19. Nicholson KL, Jones HE, Balster RL (1998). Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine. Behav Pharmacol 9:231-243.
20. Nicholson KL, Hayes BA, Balster RL (1999). Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology 146:49-59.
21. Palmer GC (2001). Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2:241-271.
22. Palmer GC, Hutchison JB (1997). Preclinical and clinical aspects of remacemide hydrochloride. In: Excitatory Amino Acids - Clinical Results With Antagonists. Herrling PL (editor). New York: Academic Press. pp. 109-120.
23. Palmer GC, Widzowski D (2000). Low affinity use-dependent NMDA receptor antagonists show promise for clinical development. Amino Acids 19:151-155.
24. Palmer GC, Murray RJ, Wilson TCM, Eisman MS, Ray RK, Griffith RC et al. (1992). Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Epilepsy Res 12:9-20.
25. Palmer GC, Cregan EC, Borrelli AR, Harris EW, Stagnitto ML, Colombo P et al. (1995a). Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia. J Pharmacol Exp Ther 274:991-1000.
26. Palmer GC, Stagnitto ML, Garske GE, Napier JJ, Harris EW, Kaiser FC et al. (1995b), Anticonvulsant efficacy/safety properties of 2-amino-N-(1,2-diphenylethyl)acetamide hydrochloride. J Pharmacol Exper Ther 273:1023-1031.
27. Palmer GC, Murray RJ, Schmiesing RJ, Cramer CL, Becker CW, Knowles MK, Freedman LR (1996). The low affinity NMDA receptor antagonists possess favorable efficacy/tolerability for use as antiepileptics. Epilepsia 37(Suppl. 5):24.
28. Palmer GC, Murray RJ, Cramer CL, Stagnitto ML, Knowles MK, Freedman LR et al. (1999). [S]-AR-R 15896 - A novel anticonvulsant: Acute safety, pharmacokinetic and pharmacodynamic properties. J Pharmacol Exp Ther 288:121-132.
29. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W et al. (1995). Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239-1258.
30. Porter RHP, Greenamyre JT (1995). Regional variations in the pharmacology of NMDA receptor channel blockers, implications for therapeutic potential. J Neurochem 64:614-623.
31. Stagnitto ML, Palmer GC, Garske GE, Napier JJ, McCreedy SA, Griffith RC, Blosser JC (1988). PR 1013-708, a potent anticonvulsant against maximal electroshock seizures (MES) in rodents. Soc Neurosci Abstr 14:866.
32. Subramaniam S, Donevan SD, Rogawski MA (1996). Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. J Pharmacol Exp Ther 276:161-168.
33. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989). The behavioural effects of MK-801: A comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167:127-135.
34. Weinbroum AA, Rudick V, Paret G, Ben-Abraham R (2000). The role of dextromethorphan in pain control. Can J Anaesth 47:585-596.
35. Wiley JL, Li H, Balster RL (1997). Discriminative stimulus effects of site-selective N-methyl-D-aspartate antagonists in NPC 17742-trained rats and squirrel monkeys. Psychopharmacology 132:382-388.
36. Willetts J, Balster RL (1988). The discriminative stimulus effects of N-methyl-D-aspartate antagonists in phencyclidine-trained rats. Neuropharmacology 27:1249-1256.
37. Willetts J, Balster RL (1989). Pentobarbital-like discriminative stimulus effects of N-methyl-D-aspartate antagonists. J Pharmacol Exp Ther 249:438-443.